Our mission is simple: put #PatientsFirst. With more peer-reviewed data supporting its safety and effectiveness in treating #DVT, #ClotTriever continues to stand out over continuous aspiration vacuum thrombectomy. Let the data do the talking—focus on the facts over flash.
#ClotTriever is backed by leading clinical evidence and offers ~$3,400 lower total care costs per episode compared to continuous vacuum aspiration thrombectomy.
Learn more: https://t.co/WJ6dk1SEF3
We're just 5 days away from #PEERLESS results, a Randomized Controlled Trial (RCT) of FlowTriever vs. catheter-directed thrombolytics (CDT) in #pulmonaryembolism.
Don't miss the late-breaking results during #TCT2024!
@TCTConference@wissamj123
ICYMI: We're excited to share that we're partnering with the @VenousForum and the @StopTheClot on #DEFIANCE, a prospective, multinational, randomized controlled trial (“RCT”).
The trial will evaluate and compare the clinical outcomes of symptomatic unilateral iliofemoral deep vein thrombosis (DVT) patients following treatment with mechanical thrombectomy using Inari's #ClotTriever System versus anticoagulation alone.
We look forward to collaborating in partnership with the American Venous Forum and NBCA as we advance clinical research for #deepveinthrombosis
More: https://t.co/mknC1l5qEP
Total episode care costs for endovascular treatment were nearly $3,400 lower with #ClotTriever compared to continuous aspiration vacuum thrombectomy. The cost savings with #ClotTriever were driven by lower device costs, fewer complications, minimal adjunctive procedures, and reduced readmission rates—key factors when aiming to reduce procedure time for #DVT treatment using aspiration thrombectomy.
Flow stasis is really helpful to put some tension on the Perclose when there is ozzing/bleeding with Impella. This case was a PercAx. @InariMedical@Abiomed
New Premier PE real-world evidence presented at #SIR2024 comparing PE patients treated w/ #FlowTriever System to those treated w/ Penumbra Indigo System:
- 4,000+ real-world PE patients treated with FlowTriever or Penumbra Indigo analyzed
- Groups adjusted to account for population differences
- Patients treated with FlowTriever showed significantly lower rates of in-hospital mortality, less adjunctive use of lytics
#PINCAI
Learn more: https://t.co/96rMok2m6y
#CLOUT is the largest mechanical thrombectomy study in #DVT. ClotTriever's #walltowall clot removal delivers immediate symptom relief with complete or near-complete clot removal in >90% of patients and a median EBL of 40 mL.
More: https://t.co/h55oosySNN
#NoChannels #NoCompromise #minimizebloodloss #ClotTriever
More info on CT: https://t.co/eJlWO8kROs
@lyft Can you please create a rental class for non smoking vehicles? I was hoping Comfort was going to be that class but no luck. How could any car with a driver that smokes in his vehicle qualify for a class that is supposed to be cleaner than the rest?
We're thrilled to announce the first patient enrollment in the #PEERLESS II RCT by Dr. William H. Matthai, Jr., Director of Clinical Cardiology Research and Professor of Clinical Medicine at Penn Presbyterian Medical Center. This groundbreaking study is set to compare the #FlowTriever® System against traditional anticoagulation therapy alone in the treatment of intermediate-risk #PE.
More: https://t.co/dlcQzxxNUc
We’re excited to announce that Inari Medical has agreed to acquire #LimFlow, a medical device company focused on transforming the treatment of CLTI, an advanced stage of peripheral artery disease. We look forward to welcoming LimFlow to the #InariMedical family!
Read more here: https://t.co/BRJt0AemuZ
The #InThrill thrombectomy system is now indicated for AV thrombectomy!
Check out Dr. Alex Misono's recent @CathLabDigest article for tips and tricks on how to efficiently maximize thrombus removal from AV fistulae or AV grafts using #InThrill: https://t.co/CGkL44qjzQ
Presented at #ACC23:
The #FLAME Study reported 1.9% in-hospital mortality in patients treated with #FlowTriever, a >90% reduction compared to the context arm & historical data: https://t.co/zUIlpwjHFU
Register for our upcoming webinar to learn more: https://t.co/taeR9eWW87